Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448782 | 0.88 | POLB (0.49) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL7376669 | 0.82 | GAA (0.57) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL16935663 | 0.82 | HPGD (0.56) | THRBALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9663451 | 0.81 | LMNA (0.54) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL6217623 | 0.80 | GAA (0.63) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL16935673 | 0.79 | MEN1 (0.32) | ALDH1A1POLB | |
| SCHEMBL5002774 | 0.79 | RAB9A (0.44) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL31682749 | 0.78 | GAA (0.39) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL18849447 | 0.76 | GAA (0.57) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL15139530 | 0.76 | GAA (0.57) | GAAL3MBTL1THRBATMNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | GAA 3452/4885L3MBTL1 2144/4885THRB 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.